Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$97.63 +1.38%

+$1.21 today

Market cap
$9.27B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 0.63M

Average 1.17M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$169.25M

FY 2025 · Annual

Investing Cash Flow

-$143.47M

FY 2025 · Annual

Financing Cash Flow

$309.02M

FY 2025 · Annual

-24.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$155.2M
+ D&A$10.0M
+ Stock-Based Comp$37.6M
+ Deferred Tax$0
- Working Capital-$5.9M
- Other Non-Cash-$55.7M
= Operating Cash Flow-$169.3M
- Capex$0
= Free Cash Flow-$169.3M

Analysis

FY2025 free cash flow is -$169.3M. FCF conversion is 109.1% of net income. Operating cash flow was -$169.3M, with capex of $0. The largest bridge item is Other Non-Cash at -$55.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 3, 2026
8-KCurrent reportNov 3, 2026
SC 13D/ASC 13D/A filingOct 9, 2026
8-KCurrent reportOct 7, 2026
424B5424B5 filingOct 6, 2026

Does SYRE generate free cash flow?

Spyre Therapeutics, Inc. (SYRE) generated -$169.25M of free cash flow in fiscal 2025.

How much operating cash flow does SYRE produce?

Operating cash flow was -$169.25M, before capital expenditures of $0.00.